Scholars Central

Conference abstractPublished 10 Aug 2015

Clinical application of pharmacogenomics in oncology

Authors: Xiaodong Feng

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Pharmacogenomics (PGx) plays a significant role in the pharmacotherapy of cancer, as narrow therapeutic indices, low overall response rates, rapid and severe systemic toxicity, and unpredictable efficacy are all hallmarks of cancer therapies. The implementation of pharmacogenomics in cancer treatment offers the potential for clinicians to better predict the differences in drug response, resistance, efficacy, and toxicity among chemotherapy and targeted-therapy patients, and to optimize the treatment regimens based on these differences. Accrued evidence demonstrates that PGx biomarkers related to drug-metabolizing enzymes, drug transporters, drug targets and drug-detoxifying mechanisms, play critical roles in predicting the safety, toxicity, and efficacy of cancer therapy in individuals or groups of patients. With clinically important biomarker polymorphisms becoming increasingly delineated, the need for clinicians to understand the association of these clinically important polymorphisms with potential changes of pharmacokinetics and pharmacodynamics of certain cancer therapies has become crucial. Although the therapeutic application of PGx research in cancer treatment during the past decade has been initially slow, the accumulating evidence of bench work and bedside patient care has been growing exponentially. By identifying specific PGx biomarkers present in tumors, physicians can select and tailor a patient’s treatment based on his or her genetic profile. Furthermore, it has become clear that the clinical benefit associated with these therapeutic agents targeted at the specific biomarkers is typically limited to a subset of responsive patients with or without a specific genomic mutation of the biomarkers. Thus, targeted therapy guided by PGx biomarkers has the potential to significantly improve the prognosis of selective cancer patients and avoid the costly unresponsive treatment for the nonselective patients to save valuable time for other proper treatments. There is an unprecedented urgency for more clinicians to become trained on how to interpret data from PGx testing and to prepare for the upcoming future of health careâ??personalized medicine.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Pharmaceutical Care & Health Systems.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmaceutical Care & Health Systems
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Xiaodong Feng”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels